DNDN
RT @BiotechStockRsr: No adverse impact on $DNDN Provenge from the $AMGN denosumab news, by the way. Products are complimentary .
DNDN
No adverse impact on $DNDN Provenge from the $AMGN denosumab news, by the way. Products are complimentary and not competitive.
DNDN
@DogDayAftern00n $dndn is the only drug that will help, FDA at it's best!
DNDN
@cacacemike What's right to you and me ain't always right to the statistical lunatics at the FDA $DNDN
DNDN
$dndn approval a must! It's only right!
DNDN
Update on $MDVN $JNJ $DNDN prostate cancer drugs http://bit.ly/ccucjw
DNDN
@DogDayAftern00n $bcrx $dndn $appl $dndn $seed I want my mommy how can you have any pudding if you don't eat your meat!"
"You! Yes
DNDN
@bearcharts $DNDN Read that article. Many flaws in it. SeekingAlpha sucks anyways. Glad you got calls - smart man.
DNDN
Got completely stopped out of $DNDN today. Unfortunately, I wish I got stopped on some other ones too. :( $YGE $AMZN $GOOG $TNA $TYH
DNDN
@bearcharts FYI I think you're nuts for holding a stock like $DNDN overnight. FDA approval could come at any time.
DNDN
long $DNDN @ 29.46, might sell Feb 30 or 31 calls later
DNDN
sold balance $DNDN calls +.10 refust to let it turn into loser
DNDN
sold half $DNDN calls +.32 just in case it gets dragged further by market
DNDN
$$ Some charts to keep an eye on tomorrow http://bit.ly/cv6FRA $DNDN, $SPR, $JLL
DNDN
Third time $DNDN closed at or within a penny of 30.42. Putting a hard stop for 1/2 at 30, 1/4 at 29.50, and 1/4 at 5% stop-loss.
DNDN
$DNDN, $MCD just name a few, made new high, they made into hint list two days ago. All big moves start with a hint day.http://bit.ly/agb9MJ
DNDN
3 fantastic days for $DNDN. Please do yourself a favor & investigate Dendreon, then invest your money. Get in now, huge upside still ahe
DNDN
RT @SellPuts: $DNDN is one if not the most volatile stocks out there.. she will take u out back and whip you <- Yup I got marks on my bac
DNDN
@desolacapital $DNDN is one if not the most volatile stocks out there.. maybe $RMBS is a second.. she will take u out back and whip you
DNDN
Someone is hiding their offer size at that 30.50 level in $DNDN, shook me out...
DNDN
$DNDN chart .. great 3 day trend. http://chart.ly/5x3a39 .. nice trade @alphatrends
DNDN
all time closing high in $DNDN 30.36
DNDN
@alphatrends nice ... You own $DNDN ...always have
DNDN
doing very little today, $DNDN holds up very well and staying above 30 could set it up for bigger breakout, i'm long calls
DNDN
$DNDN announced webcast presentation @12th Bio CEO and investor conference. Tues 2/9 @ 2pm $30!!
Dendreon Corp. - DNDN Insiders
No Insiders
We have no insiders for Dendreon right now.
Know someone who is an insider on Dendreon Corp.?
Let us know.
Dendreon Corp. - DNDN information
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics that harness the immune system to fight cancer. The company’s product portfolio includes active cellular immunotherapy, monoclonal antibodies, and small molecules products candidates to treat a range of cancers. Its product candidate include Provenge (sipuleucel-T), an active cellular immunotherapy that has completed 2 Phase III clinical trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; Neuvenge (lapuleucel-T), which has completed phase 1 clinical trials for the treatment of breast, ovarian, and colon cancers. The comp......
www.dendreon.com
484 Employees
Founded in 1992
DENDREON CORP (DNDN:NASDAQ GM)
LAST $32.91 USD
CHANGE TODAY +0.13 0.40%
VOLUME 2.7M
As of 5:20 PM 07/30/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of DENDREON CORP (DNDN)
|
OPEN
$32.25
|
PREVIOUS CLOSE
$32.78
|
|
|
DAY HIGH
$33.37
|
DAY LOW
$32.25
|
|
|
52 WEEK HIGH
04/30/10 - $57.67
|
52 WEEK LOW
08/17/09 - $21.25
|
|
|
MARKET CAP
4.5B
|
AVERAGE VOLUME 10 D
3.7M
|
|
|
EPS TTM
$-1.55
|
SHARES OUTSTANDING
135.2M
|
|
|
DNDN Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for DENDREON CORP (DNDN)
Dendreon Corp. Presents at BofA Merrill Lynch Investment Conference, Sep-13-2010
07/26/2010
Dendreon Corp. Presents at BofA Merrill Lynch Investment Conference, Sep-13-2010 . Venue: The Ritz-Carlton, 600 Stockton Street, San Francisco, California, United States.
Dendreon Corp., Q2 2010 Earnings Call, Aug-03-2010
07/12/2010
Dendreon Corp., Q2 2010 Earnings Call, Aug-03-2010
Dendreon Corp. expected to report Fiscal Year 2010 results on March 11, 2011. This event was calculated by Capital IQ (Created on June 27, 2010).
06/27/2010
Dendreon Corp. expected to report Fiscal Year 2010 results on March 11, 2011. This event was calculated by Capital IQ (Created on June 27, 2010).
DNDN Competitors
| Company | Last | Change |
| Generex Biotechnology Corp | $0.40 USD | +0.04 |
| MannKind Corp | $6.91 USD | +0.05 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | DNDN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 46,838.3x |
|
| Price/Book | 11.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 41,838.0x |
|
|
DNDN |
||
|
DNDN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Dendreon Corp. - DNDN news
Dendreon Continues to Suffer From Misleading Reports
2010-07-30 09:34:01
Quote: By Elliot TurnerIn afterhours trading Wednesday, shares of Dendreon (DNDN) went on a roller coaster ride that saw prices drop from its closing price of $33.39 to below $30 in a matter of minutes.Within the next half hour the stock once again reached its closing price and proceeded to trade all the way up to $33.89, up $0.50 cents from the day’s close.On what other stock would you see the following two articles posted within minutes of each other? The first sent Dendreon on its wild plunge:...Read article
New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
2010-07-29 08:46:22
Keywords: New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study, dndn
Quote: To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.Dendreon ON CALL at 1-877-336-3736. About Activ...Read article
Dendreon's Provenge Questioned in NEJM
2010-07-29 08:46:22
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: SEATTLE (TheStreet) --The ability of Dendreon's(DNDN) Provenge to prolong the survival of prostate cancer patients without having any measurable effect on the tumor is called "surprising" and "hard to understand" in an editorial published Wednesday night in the New England Journal of Medicine.New England Journal of Medicine (NEJM), are particularly new or surprising. But the imprimatur of the NEJM, the most prestigious medical journal in the country, does carry weight with doctors and patients.D...Read article
A.M. Vitals: Sanofi Likely to Formally Offer to Buy Genzyme
2010-07-29 08:46:21
Quote: : Sanofi-Aventis, which last week thehad made an informal acquisition approach to biotech Genzyme, is preparing to make it official, the : The question of how to stem the abuse of long-acting painkillers such as OxyContin is a hot issue, and now Washington State has its own solution — strict rules for doctors who prescribe such medicines, the : Health insurers as well as hospitals, lab-testing outfits and physician-billing companies all report that the recession has tamped down demand for ...Read article
Cancer Vaccines: Northwest Biotherapeutics vs. Dendreon
2010-07-19 01:48:31
Quote: As a followup to our interview with Northwest Biotherapeutics’(NWBO.OB) Chairman of the Board of Linda Powers, this article focuses onthe “hard differentiators” between NWBO’s immunotherapy vaccineplatform and that of their closest competitor Dendreon Corporation(DNDN).Observers and investors of Northwest Biotherapeutics now believe thecompany’s DCVaxmay be poised to surpass Dendreon’s product in thefield of vaccine based cancer treatments. Speculators have be...Read article
The Price Of Ultra-Safe Drugs
2010-07-19 01:48:30
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: But if long safety studies are always required, high prices -- like the $93, 000-per-patient for Dendreon's Provenge or even the $409,500-a-year for Alexion's Soliris --are the only approach drug companies can take.
"I guess paying high absoluteprices for medicines is going to become the new norm," writes Lilienfeld. "I wonder if that's whatAmericans had in mind--or understand tobe the price of ultra-safe drugs."
I've always thought fixing the intellectual property system to account for this...Read article
Baby Bull Market With Painful Birth Or Just Another Bounce?
2010-07-19 01:48:29
Quote: Dendreon comes out with news it will help cure cancer back in April, then sees the stock price cut in half.
Make money in market meltdowns and runaway bulls. LarryMcMillan's Daily Volume Alerts subscribers scored big recently withplays on UAL Corp., Genworth Financial and Psychiatric Solutions. Click here forinstant access to today's and Monday's trades.
You have to learn the rules on how to trade this market, or you will just be a pawn for the maestro.This market must be timed righ...Read article
Anonymous Email Slams Dendreon Stockholders
2010-07-19 01:48:28
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: The Dendreon saga keeps getting stranger. An anonymous email circulated among investors led to a sell- off in shares of Seattle-based Dendreon yesterday, but the arguments it made about the company's prostate cancer treatment Provenge don't appear to hold up to scrutiny.
The 27-page email, embedded below, does focus in on one of the biggest vulnerabilities in the studies that resulted in Provenge being approved by the Food and Drug Administration: the nature of the placebo group to which the tre...Read article
Dendreon to Host Conference Call on August 3rd to Announce Second Quarter Financial Results
2010-07-13 02:48:07
Keywords: Dendreon to Host Conference Call on August 3rd to Announce Second Quarter Financial Results, dndn, earnings
Quote: Time: 4:30 PM ET / 1:30 PM PTDate: August 3, 2010Dial-in: 1-800-901-5247 (domestic) or +1-617-786-4501 (international); conference pass code: 32238437Webcast: www.dendreon.com (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 82853835. The replay will be available from 7:30 pm ET on Tuesday, A...Read article
Why Medicare Is Reviewing Provenge
2010-07-02 01:05:57
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: Shares in Dendreon, maker of the prostate cancer cell therapy Provenge, are down 10% in morning trading as the Centers for Medicare and Medicaid Services begin a 12-month process to decide in what instances it will cover use of the pricey treatment. (See the announcement here.)
The move shocked investors, who had already been bidding down Dendreon shares because of worries that the company will face difficulties in getting insurers and the government to pay for Provenge, which is designed to...Read article
Life after the Flash Crash
2010-07-02 01:05:56
Keywords: stock, market, crash, sec, trading
Quote: Still, stocks like Dendreon(DNDN -news-people), which lost over half of its multibillion-dollar market cap in less than a minute in 2009 due to some hocus pocus trading, are anxious to see this list expanded even further. Not one to miss a competitive opportunity, Nasdaq announced Volatility Guard, a souped-up version of the SEC's automated circuit breaker program. This approach calls for trading halts in individual stocks based upon very narrow percentage price movements within thirty second ti...Read article
Dendreon: Medicare reviewing Provenge coverage
2010-07-02 01:05:55
Keywords: Dendreon: Medicare reviewing Provenge coverage, dndn,san
Quote: NEW YORK -- Medicare administrators say they will take a full year to review Dendreon Corp.'s prostate cancer therapy Provenge and decide whether to cover the costly treatment.Provenge, which costs $93,000 for a course of treatment, has been widely expected to bring Dendreon billions in revenue in the coming years. But sales will be slashed if Medicare decides not to cover the cost or offers only limited coverage. Medicare's Coverage and Analysis Group will propose a decision in about nine month...Read article
Glum Market Could Set Up Earnings Rally
2010-07-02 01:05:54
Keywords: Glum Market Could Set Up Earnings Rally, apol,dndn,sol,stz,swhc, ideas-and-strategies
Quote: Dendreon said the announcement did not restrict local Medicare contractors from covering Provenge. "Therefore, Medicare beneficiaries are still able to access Provenge and private payers can also still cover Provenge," the company said in a statement. Dendreon's Provenge therapy was approved in April and costs a total of $93,000 for the full treatment of three infusions.Shares of Dendreon fell by -6.8% on the news. A total of Fun and informative, tickerspy.com is a free investing website where y...Read article
The Provenge Dilemma: Who Gets Dendreon's New Therapy?
2010-07-01 02:29:21
Quote: By Katherine Hobson
cleared by the FDA, eligible patients are understandably anxious to get their hands on it.
Bloomberg News reports, until Dendreon can ramp up production next year, it can treat only about 2% of the patients who are medically qualified to receive the therapy. Provenge isn’t like a regular drug; patients must have their cells shipped to a lab where an individualized immune therapy will be prepared using the cells and a bioengineered version of a protein specific to cancer...Read article
[$$] A Conservative Play on a Stalled Go-Go Stock
2010-07-01 02:29:21
Quote: Dendreon (ticker: DNDN), however, is one of those stocks that should appeal to both classes of investors. The biotechnology stock,up roughly 700% in two-years, is near the top of a covered-call trading menu of the Russell 1000 Index stock. The index is comprised of large-capitalization stocks.
The covered-call strategy is primarily used by people who own stocks and want to sell calls options with higher strike prices to generate extra income through the premiums pocketed by selling the calls. Th...Read article
UPDATE - Medicare looking at Dendreon cancer vaccine
2010-07-01 02:29:19
Keywords: Pharmaceuticals (sub-industry),United States of America,Health and medicine,Washington / US Government News,Regulation and enforcement,Biotechnology,Healthcare,General News,Nature Society and Science,Politics International Affairs and Law,Domestic Politic
Quote: UPDATE 3-Medicare looking at Dendreon cancer vaccine
* Medicare weighs nationwide coverage policy for Provenge * Dendreon shares drop 23 percent on news * Proposed decision expected by March 30(Adds company comment)Lisa Richwine WASHINGTON, June 30 (Reuters) - The U.S. Medicare program
said on Wednesday it was evaluating data on Dendreon Corp's
(DNDN.O) prostate cancer therapy to decide whether to cover the
product for seniors nationwide. Shares of the company fell 23 percent to $25 on the news...Read article
Dendreon Statement on CMS National Coverage Analysis
2010-07-01 02:29:19
Keywords: Dendreon Statement on CMS National Coverage Analysis, dndn
Quote: Dendreon welcomes the opportunity to continue our discussions with CMS about how PROVENGE will be provided to Medicare beneficiaries, particularly given the survival benefit and safety profile of PROVENGE. We plan on continuing to work closely with CMS during this process to ensure patients with advanced prostate cancer have broad access to PROVENGE. Clinical Trial Results Supporting U.S. Food and Drug Administration (FDA) ApprovalThree Phase 3 studies involving 737 patients were submitted t...Read article
Skymark Research Initiates Independent Research Coverage on Dendreon Corp.
2010-06-24 09:02:04
Keywords: Skymark Research Initiates Independent Research Coverage on Dendreon Corp., dndn
Quote: Press ReleaseSource: Skymark ResearchOn Wednesday June 23, 2010, 9:15 am EDTCALGARY, Alberta, June 23, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Dendreon Corp. (Nasdaq: -Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research a...Read article
Select Stocks Outperform In Rough Week For Biotechs
2010-06-23 05:20:57
Keywords: Select Stocks Outperform In Rough Week For Biotechs, abii,amln,dndn,idix,imgn,miti,nbix,vvus, ideas-and-strategies
Quote: Given its volatility, the biotech sector is not well suited for risk-averse investors, but despite underperforming the market substantially over the past five sessions, prudent stock pickers managed to find double-digit gains in a handful of high fliers.the Biotechnology Stocks Index has slipped by -4% over the past week, ranking it among the 15 worst performing tickerspy Indexes for the period.Recent laggards include DendreonDNDNNewsFDA approval of its Provenge prostate cancer vaccine, and Vivu...Read article
FDA approves Sanofi-Aventis prostate cancer drug
2010-06-18 02:40:27
Keywords: FDA approves Sanofi-Aventis prostate cancer drug, dndn,san
Quote: It cleared Dendreon Corp.'s immune-based therapy Provenge in April. The agency said prostate cancer is the second most common cancer among men in the U.S. The disease usually occurs in older men.The ruling on Jevtana came more than three months early, as the FDA was scheduled to make a decision on the drug by Sept. 30. The drug was developed under the name cabazitaxel. Jevtana is also being reviewed by regulators in other markets, including the European Union.Sanofi-Aventis shares slid 12 cents ...Read article